Welcome to our dedicated page for Lobe Sciences news (Ticker: LOBEF), a resource for investors and traders seeking the latest updates and insights on Lobe Sciences stock.
Lobe Sciences Ltd. (OTC: LOBEF) is a pioneering force in advanced scientific instrumentation and data-driven research solutions. This news hub provides stakeholders with timely updates on corporate developments, technological breakthroughs, and strategic initiatives shaping the biotechnology and scientific analytics sectors.
Access official press releases covering earnings announcements, product launches, research milestones, and partnership agreements. Our curated feed ensures investors and industry professionals stay informed about LOBEF's innovations in precision instrumentation and analytical software platforms.
Key updates include regulatory filings, intellectual property developments, and progress in therapeutic research applications. All content is sourced directly from company communications to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Lobe Sciences' latest advancements in neurobiology research tools and AI-powered data analytics solutions. Regularly updated to reflect the company developments driving modern scientific discovery.
Lobe Sciences (OTCQB: LOBEF, CSE: LOBE), a biopharmaceutical firm specializing in transformative medicines for rare diseases, has appointed Wesley Ramjeet to its Board of Directors. Ramjeet, CEO and Founder of PPMT Strategic Group, brings over two decades of strategic financial expertise, with notable achievements in acquisitions, IPOs, and growth initiatives across various industries. His leadership has driven significant growth and successful exits, including a 30x increase for MD Logic Wellness and a notable turnaround for a medical device company. CEO Philip J Young highlighted Ramjeet's strategic insights as key for Lobe's mission to advance innovative treatments for neurological disorders.
Ramjeet has also made significant contributions to the nonprofit sector, including founding Lions Unleashed and serving on the Board of Trustees for the Universal Hip Hop Museum. He is a CPA and holds a degree in Accounting from St. John’s University.
Lobe Sciences announced that Frederick D. Sancilio Ph.D. is joining its Board of Directors. Dr. Sancilio brings over 40 years of experience in pharmaceutical sciences, founding multiple successful companies, including aaiPharma. His expertise is expected to boost Lobe's efforts in developing treatments for rare diseases and mental health conditions. The company aims to leverage his experience to advance its L-130 oral psilocin program and expand the reach of Altemia, a medical food for Sickle Cell Disease. Dr. Sancilio's previous roles include significant contributions to drug development and FDA approvals.
Lobe Sciences announced that Dr. Harry Jacobson, a former director at Merck and Vanderbilt Vice-Chancellor, will join its Board of Directors. Dr. Jacobson boasts over three decades of experience in healthcare, biotechnology, and medical innovation. His background includes roles such as Vice Chancellor for Health Affairs at Vanderbilt University Medical Center, where he expanded the budget from $750M to $2.5B. He has also founded and co-founded multiple companies, including Renal Care Group and Contact Software, and has served on the boards of Merck, Kinetic Concepts, and Renal Care Group. Dr. Jacobson’s addition is expected to drive Lobe’s development and commercialization of treatments for Chronic Cluster Headaches and Sickle Cell Disease.
Lobe Sciences (OTCQB: LOBEF) and Clearway Global have announced a change of control, with Clearway gaining voting control of Lobe.
This follows Lobe's acquisition of Altemia & Company, resulting in Clearway owning 52.69% of Lobe's shares. The companies aim to enhance growth strategies, including appointing new board members, securing funding, and addressing accounts payable.
Lobe has issued 16,424,220 shares to Clearway under a consulting agreement. The focus will be on Lobe’s L-130, an oral Psilocin-based drug, with plans for an investor communications program to share recent trial data and unlock shareholder value. The Annual General Meeting is scheduled for July 22, 2024.
FAQ
What is the current stock price of Lobe Sciences (LOBEF)?
What is the market cap of Lobe Sciences (LOBEF)?
